Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas

Chronic activation of B-cell receptor (BCR) signaling via Bruton tyrosine kinase (BTK) is largely considered to be one of the primary mechanisms driving disease progression in B–Cell lymphomas. Although the BTK-targeting agent ibrutinib has shown promising clinical responses, the presence of primary...

Descripción completa

Detalles Bibliográficos
Autores principales: George, Bhawana, Mullick Chowdhury, Sayan, Hart, Amber, Sircar, Anuvrat, Singh, Satish Kumar, Nath, Uttam Kumar, Mamgain, Mukesh, Singhal, Naveen Kumar, Sehgal, Lalit, Jain, Neeraj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281539/
https://www.ncbi.nlm.nih.gov/pubmed/32455989
http://dx.doi.org/10.3390/cancers12051328

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281539/
https://www.ncbi.nlm.nih.gov/pubmed/32455989
http://dx.doi.org/10.3390/cancers12051328

Ejemplares similares